201 related articles for article (PubMed ID: 27811606)
21. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
22. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
23. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
Dillard LK; Lopez-Perez L; Martinez RX; Fullerton AM; Chadha S; McMahon CM
Cancer Epidemiol; 2022 Aug; 79():102203. PubMed ID: 35724557
[TBL] [Abstract][Full Text] [Related]
24. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
25. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
27. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
[TBL] [Abstract][Full Text] [Related]
28. Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association.
Sherief LM; Rifky E; Attia M; Ahmed R; Kamal NM; Oshi MAM; Hanna D
Medicine (Baltimore); 2022 Nov; 101(45):e31627. PubMed ID: 36397425
[TBL] [Abstract][Full Text] [Related]
29. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
[TBL] [Abstract][Full Text] [Related]
30. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
31. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
32. Ototoxicity monitoring in children treated with platinum chemotherapy.
Brooks B; Knight K
Int J Audiol; 2018 Sep; 57(sup4):S34-S40. PubMed ID: 28737048
[TBL] [Abstract][Full Text] [Related]
33. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
Li Y; Womer RB; Silber JH
Eur J Cancer; 2004 Nov; 40(16):2445-51. PubMed ID: 15519518
[TBL] [Abstract][Full Text] [Related]
34. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
35. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
[TBL] [Abstract][Full Text] [Related]
36. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.
Waissbluth S; Peleva E; Daniel SJ
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1187-1196. PubMed ID: 27245751
[TBL] [Abstract][Full Text] [Related]
37. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
39. Practical grading system for evaluating cisplatin ototoxicity in children.
Chang KW; Chinosornvatana N
J Clin Oncol; 2010 Apr; 28(10):1788-95. PubMed ID: 20194861
[TBL] [Abstract][Full Text] [Related]
40. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.
Gupta AA; Capra M; Papaioannou V; Hall G; Maze R; Dix D; Weitzman S
J Pediatr Hematol Oncol; 2006 Feb; 28(2):91-4. PubMed ID: 16462581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]